News

Researchers at MUSC Hollings Cancer Center are working to develop new drug combinations for people with treatment-resistant cancer.

A new modeling study provides insight for guideline-writing bodies on who should be screened for anal cancer, how often and with which method.

Two Hollings cancer researchers are the sole South Carolinians selected for a life sciences entrepreneurship accelerator.

With $26.5 million in new funding, SCTR will clear the way for the translation of research breakthroughs into clinics and communities.

A Hollings researcher is working on an idea to help oral oncologists better predict which patients are likely to develop cancer.

Two Hollings Cancer Center researchers are studying new ways to bring depression treatment to cancer survivors.

Understanding who is using the latest nicotine product – oral nicotine pouches – is the key to developing future research on the pouches' effects.

Anthony Cannella has always been willing to try the newest treatments for lymphoma. So he readily agreed to sign up for a CAR-T clinical trial at Hollings.

Children who do not meet inclusion criteria for current peds studies now have a chance through an innovative program.

MUSC study shows that long-acting antiretroviral therapy for persons living with HIV can be administered safely and effectively at home.